Collegium Pharmaceutical, Inc. Common Stock
COLLStock
$36.27+14.75%52W
Market Cap$1.20B
P/E19.09x
Div yield—
Beta0.77
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-31.76%
Price vs S&P 500 (4W)5.38%
VGM Score66.46
Market Capitalization$1.20B
P/E Ratio (Annual)19.09x
Earnings Surprise History
Q1 261.76est. 1.62
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
COLLCollegium Pharmaceutical, Inc. Common Stock | B | B | C | $36.27 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Collegium Pharmaceutical is a biopharmaceutical company that develops and commercializes treatments for ADHD and moderate to severe pain in the United States. Its marketed product portfolio includes Jornay PM for ADHD, Belbuca and Xtampza ER for pain management, the Nucynta line (Nucynta ER and IR), and Symproic.